Review
Growth hormone- secreting pituitary adenomas: from molecular basis to treatment options in acromegaly
Downloads and Tools
Volume 9, Issue 7 April 1, 2010
Pages 483 - 492
http://dx.doi.org/10.4161/cbt.9.7.11581
Authors: Simone Magnavita Sabino, Paulo Augusto Carvalho Miranda and Antonio Ribeiro-Oliveira
View affiliations Hide affiliations
- Simone Magnavita Sabino
-
Laboratory of Endocrinology, Department of Internal Medicine, Federal University of
Minas Gerais (UFMG), Avenida Alfredo Balena 110, Belo Horizonte, MG, 30130-100, Brazil
- Paulo Augusto Carvalho Miranda
-
Laboratory of Endocrinology, Department of Internal Medicine, Federal University of Minas Gerais (UFMG), Avenida Alfredo Balena 110, Belo Horizonte, MG, 30130-100, Brazil
- Antonio Ribeiro-Oliveira
-
Laboratory of Endocrinology, Department of Internal Medicine, Federal University of Minas Gerais (UFMG), Avenida Alfredo Balena 110, Belo Horizonte, MG, 30130-100, Brazil
Abstract:
Acromegaly is a disease of exaggerated somatic growth and distorted proportion arising from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Although almost never malignant, somatotropinomas may cause significant morbidity and the uncontrolled excess of GH is related to mortality 2 to 4 times higher than the expected rate. Recently, clinicians treating acromegalic patients have been aware of the importance of trying to normalize IGF-1 while GH values may differ depending on assay. Despite the significant efforts made over the last decade, little is known about the genetic causes of somatotropinomas and even less of this knowledge is applied therapeutically. In this review, we attempt to address the genetic and molecular knowledge regarding somatotropinomas and their therapeutic aspects.
Preview: